{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:34:19Z","timestamp":1791005659224,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 HL007227"],"award-info":[{"award-number":["T32 HL007227"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24 AI120834"],"award-info":[{"award-number":["K24 AI120834"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL126552"],"award-info":[{"award-number":["R01 HL126552"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL126552"],"award-info":[{"award-number":["R01 HL126552"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL126552"],"award-info":[{"award-number":["R01 HL126552"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL126552"],"award-info":[{"award-number":["R01 HL126552"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Infection with human immunodeficiency virus (HIV) is associated with higher risk for myocardial disease despite modern combination antiretroviral therapy (cART). Factors contributing to this excess risk, however, remain poorly characterized. We aimed to assess cross-sectional relationships between elevations of left atrial volume index (LAVI) and myocardial extracellular volume (ECV) fraction that have been reported in persons living with HIV and levels of circulating biomarkers of inflammation, fibrosis, and myocyte stretch among persons living with and without HIV (PLWH, PLWOH).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Participants from three cohorts of PLWH and PLWOH underwent cardiovascular magnetic resonance imaging for measurement of LAVI and ECV. Levels of circulating proteins (IL-6, sCD14, galectin-3, NT-proBNP, GDF-15, TIMP-2, MMP-2, and hsTnI) were measured using immunoassays. Associations were assessed using logistic and linear regression, adjusting for demographics, substance use, and clinical characteristics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 381 participants with and without HIV, median age (IQR) was 55.1 (51.2, 58.4) years, 28% were female, 69% were Black, and 46% were current smokers. Sixty-two percent were PLWH (<jats:italic>n<\/jats:italic>\u2009=\u2009235), of whom 88% were receiving cART and 72% were virally suppressed. PLWH had higher levels of sCD14 (<jats:italic>p<\/jats:italic>\u2009=\u2009&lt;\u20090.001), GDF-15 (<jats:italic>p<\/jats:italic>\u2009=\u2009&lt;\u20090.001), and NT-proBNP (<jats:italic>p<\/jats:italic>\u2009=\u20090.03) compared to PLWOH, while levels of other biomarkers did not differ by HIV serostatus, including IL-6 (<jats:italic>p<\/jats:italic>\u2009=\u20090.84). Among PLWH, higher sCD14, GDF-15, and NT-proBNP were also associated with lower CD4\u2009+\u2009cell count, and higher NT-proBNP was associated with detectable HIV viral load. NT-proBNP was associated with elevated LAVI (OR: 1.79 [95% CI: 1.31, 2.44]; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) with no evidence of effect measure modification by HIV serostatus. Other associations between HIV-associated biomarkers and LAVI or ECV were small or imprecise.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings suggest that elevated levels of sCD14, GDF-15, and NT-proBNP among PLWH compared to PLWOH observed in the current cART era may only minimally reflect HIV-associated elevations in LAVI and ECV. Future studies of excess risk of myocardial disease among contemporary cohorts of PLWH should investigate mechanisms other than those connoted by the studied biomarkers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-022-02835-y","type":"journal-article","created":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T12:04:32Z","timestamp":1662206672000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Circulating biomarker correlates of left atrial size and myocardial extracellular volume fraction among persons living with and without HIV"],"prefix":"10.1186","volume":"22","author":[{"given":"Tess E.","family":"Peterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Landon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina A.","family":"Haberlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Bhondoekhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Plankey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.","family":"Palella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damani A.","family":"Piggott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph B.","family":"Margolick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd T.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy S.","family":"Post","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine C.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,3]]},"reference":[{"issue":"2","key":"2835_CR1","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.amjcard.2015.10.030","volume":"117","author":"MJ Feinstein","year":"2016","unstructured":"Feinstein MJ, Bahiru E, Achenbach C, Longenecker CT, Hsue P, So-Armah K, et al. Patterns of cardiovascular mortality for HIV-infected adults in the United States: 1999 to 2013. Am J Cardiol. 2016;117(2):214\u201320.","journal-title":"Am J Cardiol"},{"issue":"11","key":"2835_CR2","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","volume":"138","author":"ASV Shah","year":"2018","unstructured":"Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis. Circulation. 2018;138(11):1100\u201312.","journal-title":"Circulation"},{"issue":"2","key":"2835_CR3","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1161\/CIR.0000000000000695","volume":"140","author":"MJ Feinstein","year":"2019","unstructured":"Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberg MS, et al. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American heart association. Circulation. 2019;140(2):e98\u2013124.","journal-title":"Circulation"},{"issue":"14","key":"2835_CR4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012241","volume":"8","author":"A Alonso","year":"2019","unstructured":"Alonso A, Barnes AE, Guest JL, Shah A, Shao IY, Marconi V. HIV infection and incidence of cardiovascular diseases: an analysis of a large healthcare database. J Am Heart Assoc. 2019;8(14): e012241.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"2835_CR5","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1001\/jamacardio.2017.0264","volume":"2","author":"MS Freiberg","year":"2017","unstructured":"Freiberg MS, Chang CH, Skanderson M, Patterson OV, DuVall SL, Brandt CA, et al. Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: results from the veterans aging cohort study. JAMA Cardiol. 2017;2(5):536\u201346.","journal-title":"JAMA Cardiol"},{"issue":"8","key":"2835_CR6","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/archinternmed.2011.151","volume":"171","author":"AA Butt","year":"2011","unstructured":"Butt AA, Chang CC, Kuller L, Goetz MB, Leaf D, Rimland D, et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med. 2011;171(8):737\u201343.","journal-title":"Arch Intern Med"},{"issue":"24","key":"2835_CR7","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1056\/NEJMoa1914279","volume":"384","author":"ZH Tseng","year":"2021","unstructured":"Tseng ZH, Moffatt E, Kim A, Vittinghoff E, Ursell P, Connolly A, et al. Sudden cardiac death and myocardial fibrosis, determined by autopsy, in persons with HIV. N Engl J Med. 2021;384(24):2306\u201316.","journal-title":"N Engl J Med"},{"issue":"18","key":"2835_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.021268","volume":"10","author":"MS Freiberg","year":"2021","unstructured":"Freiberg MS, Duncan MS, Alcorn C, Chang CH, Kundu S, Mumpuni A, et al. HIV infection and the risk of world health organization-defined sudden cardiac death. J Am Heart Assoc. 2021;10(18): e021268.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"2835_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jchf.2018.10.006","volume":"7","author":"S Erqou","year":"2019","unstructured":"Erqou S, Lodebo BT, Masri A, Altibi AM, Echouffo-Tcheugui JB, Dzudie A, et al. Cardiac dysfunction among people living with HIV: a systematic review and meta-analysis. JACC Heart Fail. 2019;7(2):98\u2013108.","journal-title":"JACC Heart Fail"},{"issue":"2","key":"2835_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jchf.2018.12.004","volume":"7","author":"CR deFilippi","year":"2019","unstructured":"deFilippi CR, Grinspoon SK. Myocardial dysfunction with contemporary management of HIV: prevalence, pathophysiology, and opportunities for prevention. JACC Heart Fail. 2019;7(2):109\u201311.","journal-title":"JACC Heart Fail"},{"key":"2835_CR11","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/ehjci\/jeab037","volume":"22","author":"KC Wu","year":"2021","unstructured":"Wu KC, Haberlen SA, Plankey MW, Palella FJ, Piggott DA, Kirk GD, et al. Human immunodeficiency viral infection and differences in interstitial ventricular fibrosis and left atrial size. Eur Heart J Cardiovasc Imaging. 2021;22:888.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"3","key":"2835_CR12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.115.004430","volume":"9","author":"N Ntusi","year":"2016","unstructured":"Ntusi N, O\u2019Dwyer E, Dorrell L, Wainwright E, Piechnik S, Clutton G, et al. HIV-1-related cardiovascular disease is associated with chronic inflammation, frequent pericardial effusions, and probable myocardial edema. Circ Cardiovasc Imaging. 2016;9(3): e004430.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"3","key":"2835_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.115.004091","volume":"9","author":"JA Luetkens","year":"2016","unstructured":"Luetkens JA, Doerner J, Schwarze-Zander C, Wasmuth JC, Boesecke C, Sprinkart AM, et al. Cardiac magnetic resonance reveals signs of subclinical myocardial inflammation in asymptomatic HIV-infected patients. Circ Cardiovasc Imaging. 2016;9(3): e004091.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"10","key":"2835_CR14","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1093\/infdis\/jiv274","volume":"212","author":"DK Thiara","year":"2015","unstructured":"Thiara DK, Liu CY, Raman F, Mangat S, Purdy JB, Duarte HA, et al. Abnormal myocardial function is related to myocardial steatosis and diffuse myocardial fibrosis in HIV-infected adults. J Infect Dis. 2015;212(10):1544\u201351.","journal-title":"J Infect Dis"},{"issue":"1","key":"2835_CR15","doi-asserted-by":"publisher","first-page":"ofaa600","DOI":"10.1093\/ofid\/ofaa600","volume":"8","author":"SR Shuldiner","year":"2021","unstructured":"Shuldiner SR, Wong LY, Peterson TE, Wolfson J, Jermy S, Saad H, et al. Myocardial fibrosis among antiretroviral therapy-treated persons with human immunodeficiency virus in South Africa. Open Forum Infect Dis. 2021;8(1):ofaa600.","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"2835_CR16","first-page":"1315","volume":"221","author":"MV Zanni","year":"2020","unstructured":"Zanni MV, Awadalla M, Toribio M, Robinson J, Stone LA, Cagliero D, et al. Immune correlates of diffuse myocardial fibrosis and diastolic dysfunction among aging women with human immunodeficiency virus. J Infect Dis. 2020;221(8):1315\u201320.","journal-title":"J Infect Dis"},{"issue":"1","key":"2835_CR17","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1161\/CIRCHEARTFAILURE.109.854943","volume":"3","author":"PY Hsue","year":"2010","unstructured":"Hsue PY, Hunt PW, Ho JE, Farah HH, Schnell A, Hoh R, et al. Impact of HIV infection on diastolic function and left ventricular mass. Circ Heart Fail. 2010;3(1):132\u20139.","journal-title":"Circ Heart Fail"},{"issue":"7","key":"2835_CR18","doi-asserted-by":"publisher","first-page":"e019709","DOI":"10.1161\/JAHA.120.019709","volume":"10","author":"H Doria de Vasconcellos","year":"2021","unstructured":"Doria de Vasconcellos H, Post WS, Ervin AM, Haberlen SA, Budoff M, Malvestutto C, et al. Associations between HIV Serostatus and cardiac structure and function evaluated by 2-dimensional echocardiography in the multicenter AIDS cohort study. J Am Heart Assoc. 2021;10(7):e019709.","journal-title":"J Am Heart Assoc"},{"key":"2835_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.529075","volume":"11","author":"TP Thomas","year":"2020","unstructured":"Thomas TP, Grisanti LA. The dynamic interplay between cardiac inflammation and fibrosis. Front Physiol. 2020;11: 529075.","journal-title":"Front Physiol"},{"issue":"4","key":"2835_CR20","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1161\/HYPERTENSIONAHA.118.11463","volume":"72","author":"MD Marques","year":"2018","unstructured":"Marques MD, Nauffal V, Ambale-Venkatesh B, Vasconcellos HD, Wu C, Bahrami H, et al. Association between inflammatory markers and myocardial fibrosis. Hypertension. 2018;72(4):902\u20138.","journal-title":"Hypertension"},{"issue":"13","key":"2835_CR21","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1136\/heartjnl-2011-300960","volume":"98","author":"J Kuusisto","year":"2012","unstructured":"Kuusisto J, K\u00e4rj\u00e4 V, Sipola P, Kholov\u00e1 I, Peuhkurinen K, J\u00e4\u00e4skel\u00e4inen P, et al. Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy. Heart. 2012;98(13):1007\u201313.","journal-title":"Heart"},{"issue":"7","key":"2835_CR22","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/jce.13234","volume":"28","author":"S Tao","year":"2017","unstructured":"Tao S, Ashikaga H, Ciuffo LA, Yoneyama K, Lima JAC, Frank TF, et al. Impaired left atrial function predicts inappropriate shocks in primary prevention implantable cardioverter-defibrillator candidates. J Cardiovasc Electrophysiol. 2017;28(7):796\u2013805.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"3","key":"2835_CR23","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1148\/radiol.2015150982","volume":"278","author":"J Eng","year":"2016","unstructured":"Eng J, McClelland RL, Gomes AS, Hundley WG, Cheng S, Wu CO, et al. Adverse left ventricular remodeling and age assessed with cardiac MR imaging: the multi-ethnic study of atherosclerosis. Radiology. 2016;278(3):714\u201322.","journal-title":"Radiology"},{"key":"2835_CR24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1532-429X-15-92","volume":"15","author":"JC Moon","year":"2013","unstructured":"Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, et al. Myocardial T1 mapping and extracellular volume quantification: a society for cardiovascular magnetic resonance (SCMR) and CMR working group of the European society of cardiology consensus statement. J Cardiovasc Magn Reson. 2013;15:92.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"1","key":"2835_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12968-020-00683-3","volume":"22","author":"N Kawel-Boehm","year":"2020","unstructured":"Kawel-Boehm N, Hetzel SJ, Ambale-Venkatesh B, Captur G, Francois CJ, Jerosch-Herold M, et al. Reference ranges (\u201cnormal values\u201d) for cardiovascular magnetic resonance (CMR) in adults and children: 2020 update. J Cardiovasc Magn Reson. 2020;22(1):87.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"14","key":"2835_CR26","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.jacc.2013.05.078","volume":"62","author":"CY Liu","year":"2013","unstructured":"Liu CY, Liu YC, Wu C, Armstrong A, Volpe GJ, van der Geest RJ, et al. Evaluation of age-related interstitial myocardial fibrosis with cardiac magnetic resonance contrast-enhanced T1 mapping: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol. 2013;62(14):1280\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2835_CR27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.pcad.2020.01.002","volume":"63","author":"A Sinha","year":"2020","unstructured":"Sinha A, Feinstein M. Epidemiology, pathophysiology, and prevention of heart failure in people with HIV. Prog Cardiovasc Dis. 2020;63(2):134\u201341.","journal-title":"Prog Cardiovasc Dis"},{"issue":"5","key":"2835_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155100","volume":"11","author":"B Grund","year":"2016","unstructured":"Grund B, Baker JV, Deeks SG, Wolfson J, Wentworth D, Cozzi-Lepri A, et al. Relevance of interleukin-6 and D-dimer for serious non-AIDS morbidity and death among HIV-positive adults on suppressive antiretroviral therapy. PLoS ONE. 2016;11(5): e0155100.","journal-title":"PLoS ONE"},{"issue":"3","key":"2835_CR29","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.000844","volume":"3","author":"AD Nordell","year":"2014","unstructured":"Nordell AD, McKenna M, Borges \u00c1, Duprez D, Neuhaus J, Neaton JD, et al. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc. 2014;3(3): e000844.","journal-title":"J Am Heart Assoc"},{"key":"2835_CR30","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.111.000422","author":"PY Hsue","year":"2012","unstructured":"Hsue PY, Scherzer R, Hunt PW, Schnell A, Bolger AF, Kalapus SC, et al. Carotid intima-media thickness progression in HIV-infected adults occurs preferentially at the carotid bifurcation and is predicted by inflammation. J Am Heart Assoc. 2012. https:\/\/doi.org\/10.1161\/JAHA.111.000422.","journal-title":"J Am Heart Assoc"},{"key":"2835_CR31","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003371","author":"H Bahrami","year":"2016","unstructured":"Bahrami H, Budoff M, Haberlen SA, Rezaeian P, Ketlogetswe K, Tracy R, et al. Inflammatory markers associated with subclinical coronary artery disease: the multicenter AIDS cohort study. J Am Heart Assoc. 2016. https:\/\/doi.org\/10.1161\/JAHA.116.003371.","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"2835_CR32","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/infdis\/jix082","volume":"215","author":"DB Hanna","year":"2017","unstructured":"Hanna DB, Lin J, Post WS, Hodis HN, Xue X, Anastos K, et al. Association of macrophage inflammation biomarkers with progression of subclinical carotid artery atherosclerosis in HIV-infected women and men. J Infect Dis. 2017;215(9):1352\u201361.","journal-title":"J Infect Dis"},{"issue":"8","key":"2835_CR33","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/infdis\/jir520","volume":"204","author":"TH Burdo","year":"2011","unstructured":"Burdo TH, Lo J, Abbara S, Wei J, DeLelys ME, Preffer F, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis. 2011;204(8):1227\u201336.","journal-title":"J Infect Dis"},{"issue":"4","key":"2835_CR34","doi-asserted-by":"publisher","first-page":"ofx262","DOI":"10.1093\/ofid\/ofx262","volume":"4","author":"JV Baker","year":"2017","unstructured":"Baker JV, Sharma S, Grund B, Rupert A, Metcalf JA, Schechter M, et al. Systemic inflammation, coagulation, and clinical risk in the START trial. Open Forum Infect Dis. 2017;4(4):ofx262.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"2835_CR35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11897-017-0343-y","volume":"14","author":"N Suthahar","year":"2017","unstructured":"Suthahar N, Meijers WC, Sillj\u00e9 HHW, de Boer RA. From inflammation to fibrosis-molecular and cellular mechanisms of myocardial tissue remodelling and perspectives on differential treatment opportunities. Curr Heart Fail Rep. 2017;14(4):235\u201350.","journal-title":"Curr Heart Fail Rep"},{"issue":"4","key":"2835_CR36","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/QAD.0000000000000545","volume":"29","author":"NI Wada","year":"2015","unstructured":"Wada NI, Jacobson LP, Margolick JB, Breen EC, Macatangay B, Penugonda S, et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS. 2015;29(4):463\u201371.","journal-title":"AIDS"},{"issue":"8","key":"2835_CR37","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/infdis\/jit025","volume":"207","author":"G M\u00e9ndez-Lagares","year":"2013","unstructured":"M\u00e9ndez-Lagares G, Romero-S\u00e1nchez MC, Ruiz-Mateos E, Genebat M, Ferrando-Mart\u00ednez S, Mu\u00f1oz-Fern\u00e1ndez M, et al. Long-term suppressive combined antiretroviral treatment does not normalize the serum level of soluble CD14. J Infect Dis. 2013;207(8):1221\u20135.","journal-title":"J Infect Dis"},{"issue":"8","key":"2835_CR38","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.jchf.2015.03.007","volume":"3","author":"EA Secemsky","year":"2015","unstructured":"Secemsky EA, Scherzer R, Nitta E, Wu AH, Lange DC, Deeks SG, et al. Novel biomarkers of cardiac stress, cardiovascular dysfunction, and outcomes in HIV-infected individuals. JACC Heart Fail. 2015;3(8):591\u20139.","journal-title":"JACC Heart Fail"},{"issue":"11","key":"2835_CR39","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018767","volume":"10","author":"J Kipke","year":"2021","unstructured":"Kipke J, Margevicius S, Kityo C, Mirembe G, Buggey J, Yun CH, et al. Sex, HIV status, and measures of cardiac stress and fibrosis in Uganda. J Am Heart Assoc. 2021;10(11): e018767.","journal-title":"J Am Heart Assoc"},{"key":"2835_CR40","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cytogfr.2019.06.003","volume":"48","author":"Z Wu","year":"2019","unstructured":"Wu Z, Zhang Z, Lei Z, Lei P. CD14: Biology and role in the pathogenesis of disease. Cytokine Growth Factor Rev. 2019;48:24\u201331.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"6","key":"2835_CR41","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/infdis\/jiq118","volume":"203","author":"NG Sandler","year":"2011","unstructured":"Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203(6):780\u201390.","journal-title":"J Infect Dis"},{"issue":"8","key":"2835_CR42","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/infdis\/jiu254","volume":"210","author":"AR Tenorio","year":"2014","unstructured":"Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014;210(8):1248\u201359.","journal-title":"J Infect Dis"},{"key":"2835_CR43","doi-asserted-by":"crossref","unstructured":"Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis. 2014;210(8):1228\u201338.","DOI":"10.1093\/infdis\/jiu238"},{"issue":"2","key":"2835_CR44","first-page":"e30","volume":"39","author":"EPC van der Vorst","year":"2019","unstructured":"van der Vorst EPC, Weber C. Novel features of monocytes and macrophages in cardiovascular biology and disease. Arterioscler Thromb Vasc Biol. 2019;39(2):e30\u20137.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2835_CR45","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3389\/fimmu.2020.00951","volume":"11","author":"J Wischhusen","year":"2020","unstructured":"Wischhusen J, Melero I, Fridman WH. Growth\/differentiation factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint. Front Immunol. 2020;11:951.","journal-title":"Front Immunol"},{"issue":"13","key":"2835_CR46","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1161\/CIRCULATIONAHA.112.129437","volume":"126","author":"TJ Wang","year":"2012","unstructured":"Wang TJ, Wollert KC, Larson MG, Coglianese E, McCabe EL, Cheng S, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham heart study. Circulation. 2012;126(13):1596\u2013604.","journal-title":"Circulation"},{"issue":"11","key":"2835_CR47","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jacc.2007.04.091","volume":"50","author":"T Kempf","year":"2007","unstructured":"Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M, Doehner W, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol. 2007;50(11):1054\u201360.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"2835_CR48","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.109.928846","volume":"122","author":"IS Anand","year":"2010","unstructured":"Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the valsartan heart failure trial. Circulation. 2010;122(14):1387\u201395.","journal-title":"Circulation"},{"issue":"6","key":"2835_CR49","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000399","volume":"2","author":"V Xanthakis","year":"2013","unstructured":"Xanthakis V, Larson MG, Wollert KC, Aragam J, Cheng S, Ho J, et al. Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening. J Am Heart Assoc. 2013;2(6): e000399.","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"2835_CR50","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41569-020-0381-0","volume":"17","author":"JP Goetze","year":"2020","unstructured":"Goetze JP, Bruneau BG, Ramos HR, Ogawa T, de Bold MK, de Bold AJ. Cardiac natriuretic peptides. Nat Rev Cardiol. 2020;17(11):698\u2013717.","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"2835_CR51","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jacc.2020.12.006","volume":"77","author":"MA Alpert","year":"2021","unstructured":"Alpert MA. Natriuretic peptides as predictors of cardiovascular events and all-cause mortality. J Am Coll Cardiol. 2021;77(5):572\u20134.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"2835_CR52","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1016\/j.jacc.2017.10.044","volume":"70","author":"CY Liu","year":"2017","unstructured":"Liu CY, Heckbert SR, Lai S, Ambale-Venkatesh B, Ostovaneh MR, McClelland RL, et al. Association of elevated NT-proBNP with myocardial fibrosis in the multi-ethnic study of atherosclerosis (MESA). J Am Coll Cardiol. 2017;70(25):3102\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2835_CR53","doi-asserted-by":"publisher","first-page":"20168","DOI":"10.1038\/s41598-019-56213-4","volume":"9","author":"EY Yang","year":"2019","unstructured":"Yang EY, Khan MA, Graviss EA, Nguyen DT, Bhimaraj A, Nambi V, et al. Relationship of extracellular volume assessed on cardiac magnetic resonance and serum cardiac troponins and natriuretic peptides with heart failure outcomes. Sci Rep. 2019;9(1):20168.","journal-title":"Sci Rep"},{"issue":"6","key":"2835_CR54","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1093\/ajh\/hpab018","volume":"34","author":"V Varadarajan","year":"2021","unstructured":"Varadarajan V, Ambale-Venkatesh B, Hong SY, Habibi M, Ashikaga H, Wu CO, et al. Association of longitudinal changes in NT-proBNP with changes in left atrial volume and function: MESA. Am J Hypertens. 2021;34(6):626\u201335.","journal-title":"Am J Hypertens"},{"issue":"27","key":"2835_CR55","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129\u2013200.","journal-title":"Eur Heart J"},{"issue":"2","key":"2835_CR56","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3349\/ymj.2010.51.2.151","volume":"51","author":"SH Tsai","year":"2010","unstructured":"Tsai SH, Lin YY, Chu SJ, Hsu CW, Cheng SM. Interpretation and use of natriuretic peptides in non-congestive heart failure settings. Yonsei Med J. 2010;51(2):151\u201363.","journal-title":"Yonsei Med J"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02835-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-022-02835-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02835-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T13:03:24Z","timestamp":1662210204000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-022-02835-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,3]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2835"],"URL":"https:\/\/doi.org\/10.1186\/s12872-022-02835-y","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,3]]},"assertion":[{"value":"5 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of the Johns Hopkins University School of Medicine and was conducted in accordance with the declaration of Helsinki. Written informed consent was obtained from all subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TTB has served as a consultant to Janssen, ViiV Healthcare, Gilead Sciences, Merck, and Theratechnologies. Other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"393"}}